期刊
ANTIBIOTICS-BASEL
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics11081009
关键词
pandrug-resistant; Klebsiella pneumoniae; Acinetobacter baumannii; Pseudomonas aeruginosa; salvage treatment; double carbapenem; newer beta-lactam-beta-lactamase inhibitors; cefiderocol; eravacycline; antimicrobial combinations
Carbapenem resistance in Gram-negative bacteria is a serious global threat, especially with the presence of difficult-to-treat and pandrug-resistant strains. These infections are associated with high mortality and limited treatment options.
Carbapenem resistance in Gram-negative bacteria has come into sight as a serious global threat. Carbapenem-resistant Gram-negative pathogens and their main representatives Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa are ranked in the highest priority category for new treatments. The worrisome phenomenon of the recent years is the presence of difficult-to-treat resistance (DTR) and pandrug-resistant (PDR) Gram-negative bacteria, characterized as non-susceptible to all conventional antimicrobial agents. DTR and PDR Gram-negative infections are linked with high mortality and associated with nosocomial infections, mainly in critically ill and ICU patients. Therapeutic options for infections caused by DTR and PDR Gram-negative organisms are extremely limited and are based on case reports and series. Herein, the current available knowledge regarding treatment of DTR and PDR infections is discussed. A focal point of the review focuses on salvage treatment, synergistic combinations (double and triple combinations), as well as increased exposure regimen adapted to the MIC of the pathogen. The most available data regarding novel antimicrobials, including novel beta-lactam-beta-lactamase inhibitor combinations, cefiderocol, and eravacycline as potential agents against DTR and PDR Gram-negative strains in critically ill patients are thoroughly presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据